MA55204A - Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer - Google Patents

Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer

Info

Publication number
MA55204A
MA55204A MA055204A MA55204A MA55204A MA 55204 A MA55204 A MA 55204A MA 055204 A MA055204 A MA 055204A MA 55204 A MA55204 A MA 55204A MA 55204 A MA55204 A MA 55204A
Authority
MA
Morocco
Prior art keywords
cancer
treatment
pathway inhibitors
improved effectiveness
effectiveness
Prior art date
Application number
MA055204A
Other languages
English (en)
Inventor
Frank Kuhnert
Caroline Liot
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA55204A publication Critical patent/MA55204A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA055204A 2019-03-06 2020-02-28 Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer MA55204A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814648P 2019-03-06 2019-03-06
US202062966760P 2020-01-28 2020-01-28

Publications (1)

Publication Number Publication Date
MA55204A true MA55204A (fr) 2022-01-12

Family

ID=70009429

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055204A MA55204A (fr) 2019-03-06 2020-02-28 Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer

Country Status (13)

Country Link
US (2) US12187792B2 (fr)
EP (1) EP3935085A1 (fr)
JP (2) JP7548924B2 (fr)
KR (1) KR20210136071A (fr)
CN (1) CN113677707A (fr)
AU (1) AU2020231343B2 (fr)
CA (1) CA3129963A1 (fr)
IL (1) IL285525A (fr)
MA (1) MA55204A (fr)
MX (1) MX2021010560A (fr)
SG (1) SG11202109003QA (fr)
TW (1) TWI845626B (fr)
WO (1) WO2020180727A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
ES2954153T3 (es) 2015-12-22 2023-11-20 Regeneron Pharma Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CN112023055A (zh) * 2020-09-14 2020-12-04 南通大学 Il-6r抑制剂及il-4r抑制剂联合用药在乳腺癌化疗药物的中的应用
WO2022117869A2 (fr) * 2020-12-04 2022-06-09 Universiteit Antwerpen Immunothérapie combinatoire associant l'il-15 et un agoniste du cd40 dans le traitement du cancer
WO2025235276A1 (fr) * 2024-05-06 2025-11-13 Icahn School Of Medicine At Mount Sinai Combinaison d'inhibiteurs du récepteur il-1, d'inhibiteurs anti pd-1 et il-4 dans le traitement du cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2532677A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
CA2646626A1 (fr) 2006-03-22 2007-09-27 Apogenix Gmbh Anticorps specifique de l'il-4 humaine pour le traitement du cancer
HUE052220T2 (hu) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
CA2664343C (fr) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. Anticorps humains a haute affinite vis-a-vis du recepteur il-4 humain
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
PL2627673T3 (pl) 2010-10-15 2018-01-31 Medimmune Ltd Terapie poprawiające funkcje płuc
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
KR102502640B1 (ko) * 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
BR112015007184A2 (pt) * 2012-10-02 2017-08-08 Bristol Myers Squibb Co combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
EP2981286A4 (fr) 2013-04-05 2016-08-24 Hoffmann La Roche Anticorps anti-il-4 et anticorps bispécifiques et leurs utilisations
RS59354B1 (sr) * 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
PT3110848T (pt) * 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
EP3328418A1 (fr) * 2015-07-29 2018-06-06 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EP3416685B1 (fr) * 2016-02-19 2024-06-26 Regeneron Pharmaceuticals, Inc. Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
CN117442719A (zh) 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
WO2019051204A1 (fr) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combinaison synergique d'agents ciblant le récepteur il4, d'interféron gamma et d'interféron alpha pour une utilisation dans le traitement du cancer de l'ovaire
WO2021062332A1 (fr) * 2019-09-27 2021-04-01 Icahn School Of Medicine At Mount Sinai Association d'inhibiteurs de la signalisation de l'il4 et de points de contrôle immunitaires pour le traitement du cancer
WO2023004420A1 (fr) * 2021-07-22 2023-01-26 Icahn School Of Medicine At Mount Sinai Double blocage de signalisation d'il-4 et de protéines de point de contrôle immunitaire pour le traitement du cancer

Also Published As

Publication number Publication date
JP2024167311A (ja) 2024-12-03
JP7548924B2 (ja) 2024-09-10
AU2020231343A1 (en) 2021-10-21
US12187792B2 (en) 2025-01-07
US20250092127A1 (en) 2025-03-20
CA3129963A1 (fr) 2020-09-10
CN113677707A (zh) 2021-11-19
JP2022523804A (ja) 2022-04-26
KR20210136071A (ko) 2021-11-16
TWI845626B (zh) 2024-06-21
AU2020231343B2 (en) 2026-03-26
WO2020180727A1 (fr) 2020-09-10
IL285525A (en) 2021-09-30
SG11202109003QA (en) 2021-09-29
TW202102537A (zh) 2021-01-16
MX2021010560A (es) 2021-11-12
US20200283518A1 (en) 2020-09-10
EP3935085A1 (fr) 2022-01-12

Similar Documents

Publication Publication Date Title
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP3937932A4 (fr) Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
EP3661553A4 (fr) Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3706753A4 (fr) Inhibiteurs de la voie de l'adénosine pour le traitement du cancer
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP3645739A4 (fr) Procédés et compositions pour le traitement du mélanome
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3442505A4 (fr) Associations pour le traitement de néoplasmes à l'aide du ciblage de cellules inactives et d'inhibiteurs de l'egfr
EP3814525A4 (fr) Méthodes de traitement et biomarqueurs pour des inhibiteurs de mdm2
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3968987A4 (fr) Méthodes et substances pour le traitement du cancer
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3687537A4 (fr) Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple
EP3873205A4 (fr) Substances et méthodes pour le traitement du cancer
EP3870104A4 (fr) Méthodes et substances pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3347010A4 (fr) Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer